

WeirFoulds represents StageZero Life Sciences in its closing of a convertible debenture financing

March 11, 2020

On February 19, 2020, StageZero Life Sciences Ltd. ("StageZero", or the "Company") (TSXV: SZLS) [announced](#) the final closing of its non-brokered private placement offering of convertible debentures (each a "Debenture") for gross proceeds of \$1,180,000.

StageZero was represented by WeirFoulds LLP, with a team consisting of Rob Eberschlag, Aashima Singh (securities), Dan Thomson (financial services), and Claire Davis (articling student).

The Debentures, issued in increments of \$1,000, bear interest at a rate of 6% per annum, have a term of 18 months from the date of issue and are convertible into units. Each Unit consists of one common share of the Company and one-half of a common share purchase warrant.

[StageZero](#) is a Canadian company which is focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications.

WeirFoulds is pleased to have assisted StageZero in the transactions.

To learn more about our Securities Practice Group or to contact one of our securities lawyers, visit our [securities practice group overview page](#).

WeirFoulds^{LLP}

www.weirfoulds.com

Toronto Office

4100 – 66 Wellington Street West
PO Box 35, TD Bank Tower
Toronto, ON M5K 1B7

Tel: 416.365.1110
Fax: 416.365.1876

Oakville Office

1320 Cornwall Rd., Suite 201
Oakville, ON L6J 7W5

Tel: 416.365.1110
Fax: 905.829.2035